Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer), confirmed by a tissue biopsy — those with a pure small cell or neuroendocrine type of prostate tumour are not included
- People who have imaging scans (CT, MRI, or PET) showing that the cancer has spread to other parts of the body
- People whose cancer has previously gotten worse while on one of the following hormone-blocking treatments: darolutamide, abiraterone, enzalutamide, or apalutamide (or a combination of these), shown by rising PSA levels or changes on imaging scans
- People who are planned to start treatment with enzalutamide, abiraterone acetate, darolutamide, or apalutamide within the next 6 weeks
- People whose testosterone levels are at castrate levels (very low, below 50 ng/dl) or who are currently on androgen deprivation therapy (treatment to lower testosterone)
- People whose cancer is currently progressing, shown by a PSA level that has risen on at least two separate tests at least 2 weeks apart, with a minimum PSA of 1.0 ng/dl
- People aged 18 years or older
- People who are willing and able to read, understand, and sign a written consent form
Who may not be able to join:
- People who have a current or past serious medical or psychiatric condition — including an active stage IV cancer of another type — that would make regular blood draws difficult or unsafe, as determined by the trial investigators
- People who are unwilling to have repeated blood tests taken over time to track certain cancer markers in the blood
- People with a life expectancy of less than 6 months
- People who are planned to receive radiation therapy or other systemic (whole-body) treatments alongside the study treatment, apart from androgen deprivation therapy and bone-strengthening medications
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Andrew Armstrong, MD, Duke University
Phone: 919-684-8299
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Comparison of progression-free survival (PFS) between biomarker positive and negative participants
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.